Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 368-381

  Collet, Jean Philippe ^a   Kerneis, Mathieu ^a   Hulot, Jean Sebastien ^a   O’Connor, Stephen A ^a   Silvain, Johanne ^a   Mansencal, Nicolas ^b,c   Brugier, Delphine ^a   Abtan, Jérémie ^a   Barthélémy, Olivier ^a   Vignalou, Jean Baptiste ^a   Payot, Laurent ^a   Rousseau, Hélène ^d,e   Vicaut, Eric ^d,e   Montalescot, Gilles ^a  

^a Sorbonne Universités   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Antiplatelet drugs; Atherothrombosis; Clinical trials; Pharmacodynamics; Platelet pharmacology

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; DRUG METABOLISM; DRUG RESPONSE; FEMALE; FOLLOW UP; GENETIC SCREENING; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PLATELET REACTIVITY; POINT OF CARE TESTING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE FUNCTION; ALLELE; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMISTRY; CLINICAL TRIAL; CYTOLOGY; GENETICS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; REPRODUCIBILITY; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ACUTE CORONARY SYNDROME; AGED; ALLELES; BLOOD PLATELETS; CYTOCHROME P-450 CYP2C19; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE TESTING; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2Y12; REPRODUCIBILITY OF RESULTS; TICLOPIDINE;

EID: 84957556639     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-05-0394     Document Type: Article

References (37)

1. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. J Am Med Assoc 2011; 306: 1215–1223.
2. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013; 382: 614–623.
3. Collet J-P, Hulot J-S, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309–317.
4. Collet JP, Hulot JS, Montalescot G. Cytochrome P450 2C19 polymorphism and clopidogrel after MI. Lancet 2009; 373: 1172–1173.
5. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376: 1312–1319.
6. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-funtion allele or proton pump inhibitor co-administration: A systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134–143.
7. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250–256.
8. Cuisset T, Grosdidier C, Loundou AD, et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv 2013; 6: 854–863.
9. Fayer Rehmel JL, Eckstein JA, Farid NA, et al. Interaction of two major metabolites ofprasugrel, a thienopyridine antiplatelet agent, with the cytochromes P 450. Drug Metab Dispos 2006; 34: 600–607.
10. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429–2436.
11. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel Compared to High Loading and Maintenance Dose Clopidogrel in Patients with Planned Percutaneous Coronary Intervention: The PRINCIPLE-TIMI 44 Trial. Circulation 2007; 116: 2923–2932.
12. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–731.
13. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
14. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–2619.
15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–2015.
16. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial: the RAPID GENE trial. Lancet 2012; 379: 1705–1711.
17. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation 2010; 121: 512–518.
18. Bhatt DL, Paré G, Eikelboom JW, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J 2012; 33: 2143–2150.
19. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. J Am Med Assoc 2010; 304: 1821–1830.
20. Storhoff JJ, Marla SS, Bao P, et al. Gold nanoparticle-based detection of genomic DNA targets on microarrays using a novel optical detection system. Biosens Bioelectron 2004; 19: 875–883.
21. Saracini C, Vestrini A, Galora S, et al. Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing. Genet Test Mol Biomark 2012; 16: 500–503.
22. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9–16.
23. Kerneis M, Silvain J, Abtan J, et al. Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC Cardiovasc Interv 2013; 6: 158–165.
24. Collet JP, Hulot JS, Anzaha G, et al. High Doses of Clopidogrel to Overcome Genetic Resistance (The CLOVIS-2 study), . J Am Coll Cardiol Intv 2011; 4: 392–402.
25. Fontana P, James R, Barazer I, et al. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 2011; 9: 1664–1666.
26. Mega JL, Hochholzer W, Frelinger AL 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc 2011; 306: 2221–2228.
27. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945–1954.
28. Trenk D, Stone GW, Gawaz M, et al. A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol 2012; 59: 2159–2164.
29. Tantry US, Bonello L, Aradi D, et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischaemia and Bleeding. J Am Coll Cardiol 2013; 62: 2261–2273.
30. Collet J-P, Hulot J-S, Cuisset T, et al. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTICGENE study. Eur J Clin Pharmacol 2015; Epub ahead of print.
31. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427–2434.
32. Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100–2109.
33. Erlinge D, Gurbel PA, James S, et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol 2013; 62: 577–583.
34. Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. Am Heart J 2014; 168: 674–681.
35. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762–1771.
36. Bergmeijer TO, Janssen PWA, Schipper JC, et al. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients- Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Am Heart J 2014; 168: 16–22.e1.
37. Wang TY, Henry TD, Effron MB, et al. Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. Circ Cardiovasc Interv 2015; 8: e001712.